Alfred Chung, MD
Assistant Professor
Medicine
School of Medicine

Chung's research centers on the study and development of new therapies for plasma cell disorders, including multiple myeloma and amyloidosis (buildup of an abnormal protein called amyloid in the organs). One specific area of study is light chain amyloidosis, in which the dysfunction of certain antibody-producing cells results in abnormal protein fibers in the organs. Chung is looking specifically at targeted therapies to treat this type of amyloidosis as well as novel therapeutic strategies in the treatment of multiple myeloma.

After earning a bachelor's degree in chemical engineering at the University of Michigan, Chung earned a medical degree at Northwestern University Feinberg School of Medicine. At Stanford Medicine, he completed a residency in internal medicine, followed by a fellowship in hematology and oncology.

Chung is a member of the American Society of Clinical Oncology, American Society of Hematology and Association of Northern California Oncologists.

• Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
  Transplantation and cellular therapy 2023 Reyes KR, Huang CY, Lo M, Arora S, Chung A, Wong SW, Wolf J, Olin RL, Martin T, Shah N, Banerjee R
• Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study.
  British journal of haematology 2023 Ge AY, Huang CY, Banerjee R, Knoche J, Chung A, Arora S, Martin TG, Wolf J, Wong SW, Wiita AP, Shah N
• Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
  Current problems in cancer 2023 Kennedy VE, Natsuhara K, Maringanti SA, Shah ND, Arora S, Wolf J, Martin TG, Aras MA, Chung A, Wong SW
• Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma.
  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023 Rath C, Yoo C, Cheplowitz H, Lo M, Young R, Guglielmo J, Saunders IM, Banerjee R, Young R, Kumar A, Chung A, Rosenberg AS, Costello C, Fine J, Wilson M, Patel N, Banez MT
• Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias.
  British journal of haematology 2022 Chung A, Banbury B, Vignali M, Huang CY, Asoori S, Johnson R, Kurtz T, Arora S, Wong SW, Shah N, Martin TG, Wolf JL
• Organ responses with daratumumab therapy in previously treated AL amyloidosis.
  Blood advances 2020 Chung A, Kaufman GP, Sidana S, Eckhert E, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M
• Cutaneous plasmablastic plasmacytoma.
  Blood 2019 Chung A, Liedtke M
• Therapy-related myeloid neoplasms after treatment for plasma-cell disorders.
  Best practice & research. Clinical haematology 2019 Chung A, Liedtke M
• Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report.
  Journal of cardiothoracic surgery 2018 Beel AJ, Demos DS, Chung A, Liao C, Lui NS
• A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.
  Cancer genetics 2017 Chung A, Hou Y, Ohgami RS, Von Gehr A, Fisk DG, Roskin KM, Li X, Gojenola L, Bangs CD, Arber DA, Fire AZ, Cherry AM, Zehnder JL, Gotlib J, Merker JD
• Differential solute gas response in ionic-liquid-based QCM arrays: elucidating design factors responsible for discriminative explosive gas sensing.
  Analytical chemistry 2011 Rehman A, Hamilton A, Chung A, Baker GA, Wang Z, Zeng X
• An accurate model of polyglutamine.
  Proteins 2011 Digambaranath JL, Campbell TV, Chung A, McPhail MJ, Stevenson KE, Zohdy MA, Finke JM
• Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins.
  Molecular pharmacology 2010 Blazer LL, Roman DL, Chung A, Larsen MJ, Greedy BM, Husbands SM, Neubig RR